

FINE - LINE CIRCULARS LIMITED

REGD. OFFICE : 145 SDF - V, SEEPZ, ANDHERI (EAST), MUMBAI - 400 096.
CIN No. : L27000MH1989PLC13521 Email : finance@fine.co.in
Phone No. : 022 2829 0244/245, Fax No. : 022 2829 2554.
Website : www.fineindia.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2023

Sl. No.	Particulars	Quarter ended		Year ended	
		30.06.2023	31.03.2023	30.06.2022	31.03.2022
		(Rs. in Lakhs)	(Rs. in Lakhs)	(Rs. in Lakhs)	(Rs. in Lakhs)
1	Total income from operations (a)	300.83	733.96	690.36	2705.98
2	Net Profit/(Loss) from Ordinary Activities before Tax	(10.77)	(4.56)	5.71	6.92
3	Net Profit/(Loss) from Ordinary Activities after Tax	(10.87)	(3.76)	3.98	7.14
4	Total Comprehensive Income/(Loss) before Tax	(10.87)	(1.00)	3.98	6.94
5	Profit/(Loss) before Tax (after Extraordinary Items)	(10.87)	(1.00)	3.98	6.94
6	Reserves (Excluding Revaluation Reserve) (b)	(10.87)	(1.00)	3.98	6.94
7	Earnings Per Share (EPS) (before extraordinary items) (Rs. 10/- each - Not annualised)	(10.87)	(1.00)	3.98	6.94
8	Earnings Per Share (EPS) (after extraordinary items) (Rs. 10/- each - Not annualised)	(10.87)	(1.00)	3.98	6.94
9	Earnings Per Share (EPS) (after extraordinary items) (Rs. 10/- each - Not annualised)	(10.87)	(1.00)	3.98	6.94

Notes:
1) The above results have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 as amended.
2) The above is an extract of the Detailed Form of Quarterly Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015 and the full text of the Quarterly Financial Results is available on the Stock Exchange website (www.bseindia.com) and the Company's website (www.fineindia.com).
3) By Order of the Board
ABHAY B. DODIA
DIN: 00040641
Managing Director

Place : Mumbai
Date : 12th August, 2023

INLAND

INLAND PRINTERS LTD.
Reg. Off. 800, Sangli Elipole, Sahakar Road, Vile Parle (East), Mumbai - 400057
Tel: (022) 4042500 | Email: inlandprinters@gmail.com
CIN: L9999MH1978PLC020739 | Website: www.inlandprinters.in

EXTRACT OF STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2023

Particulars	Quarter ended		Year ended	
	30.06.2023	31.03.2023	30.06.2022	31.03.2023
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
Total Income from operation / Other income				
Net Profit/(Loss) from Ordinary Activities after Tax	(5.07)	(11.24)	(5.28)	(22.02)
Net Profit/(Loss) for the period after Tax (after Extraordinary Items)	(5.07)	(11.24)	(5.28)	(22.02)
Paid-up Equity Share Capital	502.96	502.96	502.96	502.96
Reserves (Excluding Revaluation Reserve)				(261.91)
Earnings Per Share (EPS)				
a) Basic and diluted EPS (before Extraordinary Items)	(0.10)	(0.23)	(0.11)	(0.45)
b) Basic and diluted EPS (after Extraordinary Items)	(0.10)	(0.23)	(0.11)	(0.45)

Notes:
1) The above results have been published in accordance with Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12th August, 2023. The financial results are in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016. The results have been audited by the Statutory Auditors of the Company.
2) Paid-up Equity Share Capital includes Rs. 5,50,000/- being the amount originally paid-up on forfeited shares.
3) Figures of the previous periods have been regrouped/rearranged wherever necessary to correspond with the figures of the current period.
4) The Board of Directors of Inland Printers Limited (the Transferee Company) in their meeting held on 08th March, 2023, had approved the scheme of Amalgamation under section 230 to 232 of the Companies Act, 2013 with Parity Corporate Advisory Private Limited (the Transferor Company). The said scheme is subject to the approval of the BSE and National Company Law Tribunal, Mumbai and other requisite approvals. Pending receipt of necessary approvals, no effect of the scheme has been given in the financial results for the quarter ended 30th June, 2023. The appointed date is fixed as 1st January, 2025.
5) The above is an extract of the detailed format of quarterly financial results for the quarter ended 30th June, 2023 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full text of the Quarterly Financial Results are available on the stock exchange website - www.bseindia.com and on Company's Website - www.inlandprinters.in
By Order of the Board
Kishor Sorap
Wholetime Director
DIN: 06194940

Place : Mumbai
Date : 12th August, 2023

Hedge Finance Ltd

Reg. Off.: HEDGE HOUSE MAMANGALAM PALARIVATTOM P.O., KOCHI, Kerala - 682025, CIN: U65922KL2011PLC027672

Unaudited Financial Statement for the Quarter ended 30th JUNE 2023 (Standalone)

Sl.No.	Particulars	Quarter ended			Rs. in lakhs
		June 30, 2023	June 30, 2022	March 31, 2023	
		(Unaudited)	(Unaudited)	(Unaudited)	
1	Total income from Operations	1001.30	945.31	275.20	
2	Net Profit/(Loss) for the period before Tax (Exceptional and/or Extraordinary Items)	169.89	39.95	327.33	
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary Items)	169.89	39.95	327.33	
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary Items)	128.63	30.29	238.87	
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after Tax) and Other Comprehensive Income (after Tax))	128.63	30.29	238.89	
6	Paid up Equity Share Capital	3401.65	2885.85	3401.65	
7	Reserves (excluding Revaluation Reserve)	885.48	548.25	752.85	
8	Securities Premium Account	-	-	-	
9	Net worth	4287.13	3435.30	4154.50	
10	Outstanding Debt Capital / Outstanding Debt	-	-	-	
11	Outstanding Redeemable Preference Shares *	-	-	-	
12	Debt Equity Ratio *	4.77	5.17	4.84	
13	Earnings Per Share (or Rs. 10/- each) for continuing and discontinued operations - i) Basic	0.39	0.12	0.79	
14	Capital Redemption Reserve *	0.39	0.12	0.79	
15	Debt Service coverage Ratio *	NA	NA	NA	
16	Interest Service coverage Ratio *	NA	NA	NA	

Note: a) The above is an extract of the detailed format of Quarterly / Annual Financial Results filed with the Bombay Stock Exchange (BSE) under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full text of the Quarterly / Annual Financial Results are available on the websites of the Bombay Stock Exchange (www.bseindia.com) and the Company (www.hedgefinance.com).
b) For the items referred in sub-paragraphs (a), (b), (c) and (d) of the Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015, the pertinent disclosures have been made to the Stock Exchange (specify names of Stock Exchanges) and can be accessed on the SEBI (www.bseindia.com).
For and on behalf of the Board of Directors of Hedge Finance Ltd
Sd/-
Alex Kalathil Babi
Managing Director
DIN: 01252027

Place : Kochi
Date : 11.08.2023

THOMAS SCOTT Thomas Scott (India) Limited

Regd. Office: 50, Kewal Industrial Estate, S.B. Mang. Lower Panel (W), Mumbai - 400013 Tel No.: (022) 4043 6363;
Corp. Office: 405/406, Kewal Industrial Estate, 4th Floor, S.B. Mang. Lower Panel (W), Mumbai - 400013,
website: www.thomasscott.org Email: investor.srl@bangroup.com Tel No.: (022) 6660 7965, Fax: (022) 6660 7970

Extract of Unaudited Financial Results for the Quarter Ended 30th June 2023

Particulars	Quarter ended		Year ended	
	30.06.2023	30.06.2022	31.03.2023	31.03.2022
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total income from Operations	1,910.65	2,382.61	1,288.51	6,281.58
Net Profit / (Loss) before Tax (Before Exceptional and Extraordinary Items)	115.33	261.58	74.06	297.91
Net Profit / (Loss) before Tax (After Exceptional and Extraordinary Items)	115.33	261.58	74.06	297.91
Net Profit / (Loss) after Tax (After Exceptional and Extraordinary Items)	115.02	268.22	70.79	287.94
Total Comprehensive Income	-	1.03	-	-
Total Comprehensive Income (Comprising Profit/(Loss) after Tax and other comprehensive income after Tax)	115.02	269.25	70.79	287.94
Equity Share Capital (Face value of Rs. 10/- per share)	785.27	635.67	551.44	635.67
Reserves (Excluding Revaluation Reserves as per Balance Sheet of previous year)	-	-	-	-
Earnings Per Share (of 10 each) (in Rs.)				
(a) Basic	1.46	4.24	1.28	4.53
(b) Diluted	1.46	4.24	1.28	4.53

Notes:
1) The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 12th August 2023.
2) The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
3) Figures of the previous period have been regrouped/rearranged wherever necessary/practicable to conform to the current presentation.
4) The Company is presently engaged in single business segment of manufacturing and trading of textile products. In case of segment reporting of geographical segment for quarter ended June 2023, the export turnover of the Company is nil hence, no segment reporting has been done.
For Thomas Scott (India) Limited
Sd/-
Brijgopal Bang
Managing Director
(DIN: 00112263)

Place : Mumbai
Date : 11th August 2023



GKB OPHTHALMIC LIMITED

CIN : L26109GA1981PLC000469
Regd. Office: 16-A, Trivim Industrial Estate, Mapusa Goa. 403 526
Tel No. (0832) 2257253 / 8714444 Fax No. (0832) 2257044 E-mail: gkbophthalmics@gkb.net Website: www.gkb.net

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2023

Sl. No.	Particulars	Standalone		Consolidated	
		Quarter ended	Year ended	Quarter ended	Year ended
		30.06.23	31.03.23	30.06.22	31.03.23
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Total Income from Operations	570.97	686.72	783.30	2,272.33
2	Net Profit / (Loss) for the period (before Exceptional Items and Tax)	7.38	(220.01)	5.22	(300.79)
3	Net Profit / (Loss) for the period (after Exceptional Items and before Tax)	7.38	(220.01)	5.22	(300.79)
4	Net Profit / (Loss) for the period (after Exceptional Items and before Tax)	7.38	(220.01)	5.22	(300.79)
5	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax))	7.37	(207.85)	5.60	(288.73)
6	Equity Share Capital	504.06	504.06	504.06	504.06
7	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)				
(a) Basic (Rs.)		0.15	(4.20)	0.14	(5.72)
(b) Diluted (Rs.)		0.15	(4.20)	0.14	(5.72)

Notes:
1. The financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 11, 2023.
2. The Group operates in one primary segment only i.e. Ophthalmic Lenses and therefore Ind AS 108 - Operating Segment is not applicable.
3. Board of Directors of the Company in its meeting held on August 12, 2022, had changed the accounting policy from April 1, 2022, by treating glass moulds as part of the inventory which were earlier treated as Property, Plant and Equipment (PPE) and depreciated over its expected useful life. Due to the change, Depreciation and amortisation expense for the quarter ended June 30, 2022 was lower by Rs. 31.48 lakhs and Cost of materials consumed was higher by Rs. 542 lakhs.
4. Board of Directors of the Company had reviewed the change in the aforementioned accounting policy as at the year ended March 31, 2023 and concluded that the glass moulds were to be reinstated as PPE in line with the policy followed in the year ended March 31, 2022. The impact due to this change was reflected in the 'Depreciation and amortisation expense' for the quarter ended March 31, 2023 which had increased by Rs. 95.10 lakhs and Cost of materials consumed had decreased by Rs. 34.55 lakhs. The above change had no impact on the amounts reported for the year ended March 31, 2023.
5. The figures for the quarter ended March 31, 2023 are balancing figures between the audited figures in respect of the full previous financial year and the published year-to-date figures up to the third quarter of the previous financial year which were subjected to limited review.
6. Figures of the previous periods have been regrouped/rearranged wherever necessary.
7. The above is an extract of the detailed format of quarterly / annual financial results filed with the Stock Exchange under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full text of the quarterly / annual financial results are available on the Stock Exchange website (www.bseindia.com) and on Company's website (www.gkb.net).

Place : Mapusa - Goa
Date : 11th August, 2023

For GKB Ophthalmic Limited
K.G. Gupta
Managing Director
DIN: 00051863



GLENMARK PHARMACEUTICALS LIMITED

Registered Office: S-2, Mahatma Chambers, 22, Brabham Desai Road, Andheri - 400 026.
Corporate Office: Glenmark House, B-2, Sakinaka, Off. D. Wadani Road, Wadani, Andheri (E), Mumbai - 400099.
Phone No: +91 22 4018 3999 Fax No: +91 22 4018 9985 Website: www.glenmarkpharma.com Email: corporate@corporate.glenmarkpharma.com
CIN: L24299MH1971PLC019362

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2023

(All amounts in million of Indian Rupees, unless otherwise stated)

Sl. No.	Particulars	Standalone		Consolidated	
		Quarter ended	Quarter ended	Quarter ended	Quarter ended
		30/06/2023	31/03/2023	30/06/2023	31/03/2023
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from operations	20,950.62	18,748.85	18,732.88	80,106.66
(a)	Net sales	20,950.62	18,748.85	18,732.88	80,106.66
(b)	Other operating income	430.22	640.83	588.90	2,009.96
II	Total revenue from operations	21,442.84	19,389.68	19,321.78	82,116.62
(a)	Finance cost	4,930.01	2,309.65	3,405.18	9,859.30
(b)	Interest income (I - II)	21,957.45	17,120.13	22,584.48	82,066.01
III	Expenses	7,967.58	7,770.88	7,138.42	30,366.76
(a)	Cost of materials consumed	8,213.71	8,660.54	9,400.54	39,811.52
(b)	Purchases of stock-in-trade	(230.64)	(54.20)	(300.92)	(313.65)
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	3,244.65	3,051.20	3,022.97	1,239.05
(d)	Employee benefits expense	619.54	586.60	577.63	1,100.54
(e)	Finance cost	487.52	467.29	490.30	1,841.48
(f)	Depreciation, amortisation and impairment expense	4,690.79	5,585.48	3,949.95	20,050.64
(g)	Other expenses	11,700.74	18,258.65	15,529.02	31,246.59
IV	Profit/(Loss) before extraordinary items and tax (III - IV)	4,256.74	3,455.07	3,955.48	21,877.42
V	Exceptional items (gain)/loss (after note 5)	316.29	6,580.72	4,650.68	5,011.23
VI	Profit/(Loss) before tax (V - VI)	3,920.42	(3,133.23)	6,955.48	15,716.74
VII	Tax expense	365.65	846.54	1,103.87	3,869.51
Current tax		365.65	846.54	1,103.87	3,869.51
Deferred tax		-	-	-	-
IX	Profit/(Loss) for the period (VII - VIII)	2,718.56	(1,374.69)	4,905.81	12,087.09
Profit/(Loss) for the period attributable to:					
- Non-controlling interests		-	-	-	231.94
- Owners of the Company		2,718.56	(1,374.69)	4,905.81	11,855.15
X	Other comprehensive income				
A	Items that will be reclassified to profit or loss	(7.50)	(41.64)	61.37	3.71
(i)	Income tax relating to items that will be reclassified to profit or loss	2.23	14.55	(11.36)	(23.98)
B	Items that will be reclassified to profit or loss	-	-	-	(594.37)
(i)	Income tax relating to items that will be reclassified to profit or loss	-	-	-	6.50
XI	Total comprehensive income for the period/year	2,711.09	(1,401.78)	5,008.12	12,094.01
Total comprehensive income attributable to:					
- Non-controlling interests		-	-	-	231.98
- Owners of the Company		2,711.09	(1,401.78)	5,008.12	11,862.03
XII	Paid up Equity Share Capital, Equity Shares of Rs. 10/- each	282.17	282.17	282.17	282.17
XIII	Other equity (other than revaluation reserve)	178,492.46	-	-	-
XIV	Earnings per share (EPS)				
(a) Basic (Rs. per share)		9.63	(4.87)	17.46	42.84
(b) Diluted (Rs. per share)		9.63	(4.87)	17.46	42.84

Notes:
1. The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
2. The above results were reviewed by the Audit Committee at its meeting held on 10th August, 2023 and approved by the Board of Directors at their meetings held on 11th August, 2023. The results for the quarter ended 30th June, 2023 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.
3. The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical ingredient components, which are identified and inter-dependent. Therefore, the Company has only one reportable segment, i.e., Pharmaceuticals.
4. As at 30th June, 2023, pursuant to Employee Stock Options Scheme 2010, 78,717 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
5. Exceptional item:
Exceptional item of ₹ 509.21 in the consolidated result for the quarter comprises of revaluation cost of manufacturing sites in India and Mexico (USA).
Exceptional item of ₹ 316.29 in the standalone result for the quarter comprises of revaluation cost of manufacturing sites in India.
31st March 2023:
The Company and its US subsidiary (Glenmark Pharmaceuticals Inc., USA) have, subject to final documentation and approval of the Court, after the end of the accounting year, entered into a settlement with the Plaintiff Group collectively representing all of the claims against the Company and Merck in relation to multiple antitrust and consumer protection claims, including a class action, consolidated in the Eastern District of Virginia, USA (the "Court") for a total amount of US\$ 87.5m (US Dollar Eighty Seven Point Five million), payable over two financial years. The final settlements will be in accordance with the separate agreements entered into with each of the plaintiff groups and will be subject to the final approval by the Court. The settlements will make clear that the settlements are commercial settlements of all liabilities and not on the basis of the Company having conceded any liability, offering or liability.
In view of the above and as a prudent measure, the Company has made a provision for the estimated settlement amount of ₹ 6,210.53 (equivalent of US\$ 87.5 million and related costs) and charged the same to profit or loss account for the year ended 31st March 2023. Due to the non-recurring nature of the provision, the Company has classified this provision as an exceptional item in the financial statements for the quarter and year ended 31st March 2023. The resultant deferred tax asset of ₹ 2,759.25 has also been recognized. On finalisation of settlement agreements and final approval of the Court, the crystallized liability will be accounted after adjusting the provision in this respect in the year of final settlement and Court approval.
Exceptional item in the consolidated result for the quarter also includes a net gain of ₹ 10.21 arising from the divestment of select brands and sub-brands from the dermatology segment (India and Nepal business), net of trade expenses, trade receivables, inventory write-off, other reimbursable expenses and revaluation cost of Mumbai manufacturing site (USA) and India manufacturing sites. The exceptional item for the year ended 31st March 2023 additionally includes gain on sale of cardiac brand Racer (India and Nepal business), net of trade expenses, trade receivables, inventory write-off, other reimbursable expenses and revaluation cost of Mumbai manufacturing site (USA).
Exceptional item in the standalone result for the quarter includes a net gain of

